Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 Aug 2007 |
| 100,000 Orion A-shares converted into B-shares | 6 Jul 2007 |
| 335,315 Orion A-shares converted into B-shares | 21 Jun 2007 |
| 532,051 Orion A-shares converted into B-shares | 21 May 2007 |
| 905,839 Orion A-shares converted into B-shares | 26 Apr 2007 |